Swift Biosciences and BillionToOne Partner Together for Commercialization and Manufacturing of EUA Approved COVID-19 Test

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

September 29, 2020

Swift Biosciences, a leader in Next-Generation Sequencing Manufacturing & Technology and BillionToOne, a precision diagnostics company today announced that Swift Bioscience will be the exclusive distributor of BillionToOne’s RNA extraction-free, Emergency Use Authorization (EUA) COVID-19 Test Kit for high capacity testing of up to a million tests per day. The test is designed to detect the virus that causes COVID-19 in respiratory specimens obtained from nasal swabs, nasopharyngeal swabs, or oropharyngeal swabs.

Swift Biosciences notes: The BillionToOne COVID-19 test uses different sets of instruments and chemicals from existing COVID-19 tests, enabling labs to unlock a new set of unused capacity. The BillionToOne test sequences the virus’ genome – making the test sensitive, specific, and accurate compared to other COVID-19 tests on the market.  Most notable, this test does not require RNA extraction which is costly, time-consuming, and critical supply chain demands due to flu season will not negatively affect this workflow.  Additionally, the test is easily adaptable for any clinical labs with Sanger Sequencers and requires minimal training.

BillionToOne approached Swift Biosciences in April of 2020 and asked for their assistance to manufacture and provide quality assurance shipping and logistics.  Swift has provided BillionToOne with 60,000 RUO reactions that have been adopted by DASA, the biggest medical diagnostics laboratory in Brazil.  With the EUA approval from the U.S. Food and Drug Administration (FDA), Swift will be leading all worldwide commercial efforts, except for Brazil.

“Early in the pandemic, Swift was quick to pivot and offer products for sequencing the SARS-CoV-2 genome and associated receptors like ACE2.  By including the BillionToOne’s COVID Diagnostic Test Kit into Swift’s product portfolio, it allows us the opportunity to provide the full complement of tools to assist in the fight against COVID-19 in ways that were not possible before.  Clinical laboratories can use their excess Sanger instruments to full capacity to do over 3,000 test per day per instrument,” said Nathan Wood, CEO of Swift Biosciences.

The BilliontoOne qSanger-COVID-19 Assay is available for immediate purchase, and shipment through SwiftBioSci.com for North America and Swift’s global distribution network.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.